Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451859 | 0.86 | AKR1B1 (0.61) | AKR1B1ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL4458458 | 0.85 | AKR1B1 (0.64) | AKR1B1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL4452476 | 0.83 | AKR1B1 (0.58) | AKR1B1MAPTALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL4454819 | 0.76 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL13484254 | 0.72 | AKR1B1 (0.65) | AKR1B1SMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL4458342 | 0.72 | AKR1B1 (0.43) | AKR1B1MAPTALDH1A1KDM4ECYP3A4 | |
| SCHEMBL4458218 | 0.71 | AKR1B1 (0.64) | AKR1B1MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4451364 | 0.71 | AKR1B1 (0.64) | AKR1B1MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6229563 | 0.70 | AKR1B1 (0.47) | AKR1B1MAPTALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL13211795 | 0.70 | AKR1B1 (0.63) | AKR1B1SMN1; SMN2MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1491541-B1 | Pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1491540-B1 | Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050113381-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2005-05-26 | — | — | US | disclosed |
| US-6849629-B2 | Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders | PFIZER, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1373259-B1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1373259-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2003-08-28 | — | — | US | disclosed |
| US-6579879-B2 | Pyridazinone aldose reductase inhibitors | PFIZER INC | 2003-06-17 | — | — | US | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002079198-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113381-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | AKR1B1 3/4885MAPT 2453/4885ALDH1A1 30/4885 |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | AKR1B1 3/4885MAPT 2453/4885ALDH1A1 30/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | AKR1B1 2/4885MAPT 3054/4885ALDH1A1 27/4885 |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | AKR1B1 2/4885MAPT 3741/4885ALDH1A1 30/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | AKR1B1 3/4885MAPT 3891/4885ALDH1A1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.